大连标准化公共服务平台|国际技术法规

委员会条例(EU) 2016/1179，为适应科技的进步，修订欧洲议会和理事会条例(EC) No 1272/2008(关于物质和混合物的分级、标签和包装)

技术法规类型：欧盟Eurlex法规来源：tbtmap

EURLEX ID：32016R1179

OJ编号：OJ L 195, 20.7.2016, p. 11-25

中文标题：委员会条例(EU) 2016/1179，为适应科技的进步，修订欧洲议会和理事会条例(EC) No 1272/2008(关于物质和混合物的分级、标签和包装)

原文标题：Commission Regulation (EU) 2016/1179 of 19 July 2016 amending, for the purposes of its adaptation to technical and scientific progress, Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures (Text with EEA relevance)

分类：13.30.18_危险物质

文件类型：二级立法 Regulation|条例

生效日期：2016-08-09

废止日期：2058-12-31

法规全文：查看欧盟官方文件

html PUBLIC "-//W3C//DTD XHTML//EN" "xhtml-strict.dtd"L_2016195EN.01001101.xml

20.7.2016

Official Journal of the European Union

L 195/11

COMMISSION REGULATION (EU) 2016/1179

of 19 July 2016

amending, for the purposes of its adaptation to technical and scientific progress, Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures

(Text with EEA relevance)

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006 (1), and in particular Article 37(5) thereof,

Whereas:

(1)

Part 3 of Annex VI to Regulation (EC) No 1272/2008 contains two lists of harmonised classification and labelling of hazardous substances. Table 3.1 lists the harmonised classification and labelling of hazardous substances based on the criteria set out in Parts 2 to 5 of Annex I to Regulation (EC) No 1272/2008. Table 3.2 lists the harmonised classification and labelling of hazardous substances based on the criteria set out in Annex VI to Council Directive 67/548/EEC (2).

(2)	Since Directive 67/548/EEC has been repealed with effect from 1 June 2015, Table 3.2 in Part 3 of Annex VI should be deleted. However, in order to ease the transition to full applicability of Regulation (EC) No 1272/2008, that deletion should not take effect until 1 June 2017.

(3)

Proposals for new, updated or deleted harmonised classification and labelling of certain substances have been submitted to the European Chemicals Agency (ECHA) pursuant to Article 37 of Regulation (EC) No 1272/2008. Based on the opinions on those proposals issued by the Committee for Risk Assessment of ECHA (RAC), as well as on the comments received from the parties concerned, it is appropriate to introduce, update or delete harmonised classification and labelling of certain substances.

(4)

With regard to the substance lead, RAC proposes in its scientific opinion of 5 December 2013 to classify it as toxic for reproduction category 1A. However, in view of the lack of certainty regarding the bioavailability of lead in the massive form, a distinction needs to be made between the massive form (particle size more than or equal to 1 mm) and the powder form (particle size of less than 1 mm). It is therefore appropriate to introduce a specific concentration limit (SCL) of ≥ 0,03 % for the powder form and a generic concentration limit (GCL) of ≥ 0,3 % for the massive form.

(5)

With regard to the copper substances, the environmental classification recommended in the RAC opinions of 4 December 2014 should be included in Annex VI to Regulation (EC) No 1272/2008 since sufficient scientific evidence is available justifying this new classification. However, the proposed M-factors for long-term aquatic hazard should not be included since they require further assessment by RAC in view of scientific data on aquatic toxicity presented by industry after the RAC opinion was forwarded to the Commission.

(6)	Regulation (EC) No 1272/2008 should be amended accordingly.

(7)

Compliance with the new harmonised classifications should not be required immediately, as a certain period of time will be necessary to allow suppliers to adapt the labelling and packaging of substances and mixtures to the new classifications and to sell existing stocks. This period of time will also be necessary to allow suppliers to adapt to and to comply with other legislative obligations resulting from the new harmonised classifications for substances such as those provided for in Article 22(f) or Article 23 of Regulation (EC) No 1907/2006 of the European Parliament and of the Council (3), those provided for in Article 50 of Regulation (EU) No 528/2012 of the European Parliament and of the Council (4) or those in Article 44 of Regulation (EC) No 1107/2009 of the European Parliament and of the Council (5).

(8)

In line with the transitional provisions of Regulation (EC) No 1272/2008 which allow the application of the new provisions at an earlier stage on a voluntary basis, suppliers should have the possibility of applying the new harmonised classifications and of adapting the labelling and packaging accordingly on a voluntary basis before the deadline for compliance.

(9)	The measures provided for in this Regulation are in accordance with the opinion of the Committee established by Article 133 of Regulation (EC) No 1907/2006,

HAS ADOPTED THIS REGULATION:

Article 1

Regulation (EC) No 1272/2008 is amended as follows:

(1)	Annex VI is amended in accordance with the Annex to this Regulation;

(2)	in Annex VI, Table 3.2 is deleted.

Article 2

1. This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.

2. This Regulation shall apply from 1 March 2018.

Article 1(2) shall apply from 1 June 2017.

3. By way of derogation from paragraph 2, substances and mixtures may, before 1 March 2018, be classified, labelled and packaged in accordance with Regulation (EC) No 1272/2008 as amended by this Regulation.

This Regulation shall be binding in its entirety and directly applicable in all Member States.

Done at Brussels, 19 July 2016.

For the Commission

The President

Jean-Claude JUNCKER

(1) OJ L 353, 31.12.2008, p. 1.

(2) Council Directive 67/548/EEC of 27 June 1967 on the approximation of laws, regulations and administrative provisions relating to the classification, packaging and labelling of dangerous substances (OJ 196, 16.8.1967, p. 1).

(3) Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), establishing a European Chemicals Agency, amending Directive 1999/45/EC and repealing Council Regulation (EEC) No 793/93 and Commission Regulation (EC) No 1488/94 as well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC (OJ L 396, 30.12.2006, p. 1).

(4) Regulation (EU) No 528/2012 of the European Parliament and of the Council of 22 May 2012 concerning the making available on the market and use of biocidal products (OJ L 167, 27.6.2012, p. 1).

(5) Regulation (EC) No 1107/2009 of the European Parliament and of the Council of 21 October 2009 concerning the placing of plant protection products on the market and repealing Council Directives 79/117/EEC and 91/414/EEC (OJ L 309, 24.11.2009, p. 1).

ANNEX

Table 3.1 of Part 3 of Annex VI to Regulation (EC) No 1272/2008 is amended as follows:

(a)	the entries corresponding to index numbers 607-331-00-5 and 609-066-00-0 are deleted;

(b)

the entries corresponding to index numbers, 006-035-00-8, 029-002-00-X, 602-020-00-0, 602-033-00-1, 603-055-00-4, 604-030-00-0, 604-092-00-9, 605-013-00-0, 605-022-00-X, 606-014-00-9, 606-021-00-7, 607-056-00-0, 607-059-00-7, 607-157-00-X, 607-172-00-1, 607-375-00-5, 607-623-00-2, 613-166-00-X, 613-121-00-4, 616-011-00-4, 616-037-00-6 and 616-207-00-X are replaced by the following entries respectively:

Index No	International Chemical Identification	EC No	CAS No	Classification		Labelling			Specific Conc. Limits, M-factors	Notes
Index No	International Chemical Identification	EC No	CAS No	Hazard Class and Category Code(s)	Hazard statement Code(s)	Pictogram, Signal Word Code(s)	Hazard statement Code(s)	Suppl. Hazard statement Code(s)	Specific Conc. Limits, M-factors	Notes
‘006-035-00-8	pirimicarb (ISO); 2-(dimethylamino)-5,6-dimethylpyrimidin-4-yl dimethylcarbamate	245-430-1	23103-98-2	Carc. 2 Acute Tox. 3 Acute Tox. 3 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H351 H331 H301 H317 H400 H410	GHS08 GHS06 GHS09 Dgr	H351 H331 H301 H317 H410		M = 10 M = 100’
‘029-002-00-X	dicopper oxide; copper (I) oxide	215-270-7	1317-39-1	Acute Tox. 4 Acute Tox. 4 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1	H332 H302 H318 H400 H410	GHS07 GHS05 GHS09 Dgr	H332 H302 H318 H410		M = 100’
‘602-020-00-0	1,2-dichloropropane; propylene dichloride	201-152-2	78-87-5	Flam. Liq. 2 Carc. 1B Acute Tox. 4* Acute Tox. 4*	H225 H350 H332 H302	GHS02 GHS08 GHS07 Dgr	H225 H350 H332 H302’
‘602-033-00-1	chlorobenzene	203-628-5	108-90-7	Flam. Liq. 3 Acute Tox. 4 Skin Irrit. 2 Aquatic Chronic 2	H226 H332 H315 H411	GHS02 GHS07 GHS09 Wng	H226 H332 H315 H411’
‘603-055-00-4	propylene oxide; 1,2-epoxypropane; methyloxirane	200-879-2	75-56-9	Flam. Liq. 1 Carc. 1B Muta. 1B Acute Tox. 3 Acute Tox. 3 Acute Tox. 4 STOT SE 3 Eye Irrit. 2	H224 H350 H340 H331 H311 H302 H335 H319	GHS02 GHS08 GHS06 Dgr	H224 H350 H340 H331 H311 H302 H335 H319’
‘604-030-00-0	bisphenol A; 4,4′-isopropylidenediphenol	201-245-8	80-05-7	Repr. 1B STOT SE 3 Eye Dam. 1 Skin Sens. 1	H360F H335 H318 H317	GHS08 GHS05 GHS07 Dgr	H360F H335 H318 H317’
‘604-092-00-9	phenol, dodecyl-, branched; [1] phenol, 2-dodecyl-, branched; [2] phenol, 3-dodecyl-, branched; [3] phenol, 4-dodecyl-, branched; [4] phenol, (tetrapropenyl) derivatives [5]	310-154-3 [1] [2] [3] [4] [5]	121158-58-5 [1] [2] [3] 210555-94-5 [4] 74499-35-7 [5]	Repr. 1B Skin Corr. 1C Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1	H360F H314 H318 H400 H410	GHS08 GHS05 GHS09 Dgr	H360F H314 H410		M = 10 M = 10’
‘605-013-00-0	chloralose (INN); (R)-1,2-O-(2,2,2-trichloroethylidene)-α-D-glucofuranose; glucochloralose; anhydroglucochloral	240-016-7	15879-93-3	Acute Tox. 4* Acute Tox. 3 STOT SE 3 Aquatic Acute 1 Aquatic Chronic 1	H332 H301 H336 H400 H410	GHS06 GHS09 Dgr	H332 H301 H336 H410		M = 10 M = 10	C’
‘605-022-00-X	glutaral; glutaraldehyde; 1,5-pentanedial	203-856-5	111-30-8	Acute Tox. 2 Acute Tox. 3 STOT SE 3 Skin Corr. 1B Resp. Sens. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 2	H330 H301 H335 H314 H334 H317 H400 H411	GHS06 GHS05 GHS08 GHS09 Dgr	H330 H301 H335 H314 H334 H317 H410	EUH071	STOT SE 3; H335: 0,5 % ≤ C < 5 % M = 1’
‘606-014-00-9	chlorophacinone (ISO); 2-[(4-chlorophenyl)(phenyl)acetyl]-1H-indene-1,3(2H)-dione	223-003-0	3691-35-8	Repr. 1B Acute Tox. 1 Acute Tox. 1 Acute Tox. 1 STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1	H360D H330 H310 H300 H372 (blood) H400 H410	GHS08 GHS06 GHS09 Dgr	H360D H330 H310 H300 H372 (blood) H410		Repr. 1B; H360D: C ≥ 0,003 % STOT RE 1; H372 (blood): C ≥ 0,1 % STOT RE 2; H373 (blood): 0,01 % ≤ C < 0,1 % M = 1 M = 1’
‘606-021-00-7	N-methyl-2-pyrrolidone; 1-methyl-2-pyrrolidone	212-828-1	872-50-4	Repr. 1B STOT SE 3 Skin Irrit. 2 Eye Irrit. 2	H360D*** H335 H315 H319	GHS08 GHS07 Dgr	H360D*** H335 H315 H319		STOT SE 3; H335: C ≥ 10 %’
‘607-056-00-0	warfarin (ISO); 4-hydroxy-3-(3-oxo-1-phenylbutyl)-2H-chromen-2-one; [1] (S)-4-hydroxy-3-(3-oxo-1-phenylbutyl)-2-benzopyrone; [2] (R)-4-hydroxy-3-(3-oxo-1-phenylbutyl)-2-benzopyrone [3]	201-377-6 [1] 226-907-3 [2] 226-908-9 [3]	81-81-2 [1] 5543-57-7 [2] 5543-58-8 [3]	Repr. 1A Acute Tox. 1 Acute Tox. 1 Acute Tox. 2 STOT RE 1 Aquatic Chronic 2	H360D H330 H310 H300 H372 (blood) H411	GHS08 GHS06 GHS09 Dgr	H360D H330 H310 H300 H372 (blood) H411		Repr. 1A; H360D: C ≥ 0,003 % STOT RE 1; H372 (blood): C ≥ 0,5 % STOT RE 2; H373 (blood): 0,05 % ≤ C < 0,5 %’
‘607-059-00-7	coumatetralyl (ISO); 4-hydroxy-3-(1,2,3,4-tetrahydro-1-naphthyl)coumarin	227-424-0	5836-29-3	Repr. 1B Acute Tox. 2 Acute Tox. 3 Acute Tox. 2 STOT RE 1 Aquatic Chronic 1	H360D H330 H311 H300 H372 (blood) H410	GHS08 GHS06 GHS09 Dgr	H360D H330 H311 H300 H372 (blood) H410		Repr. 1B; H360D: C ≥ 0,003 % STOT RE 1; H372 (blood): C ≥ 1,0 % STOT RE 2; H373 (blood) 0,1 % ≤ C < 1,0 % M = 10’
‘607-157-00-X	difenacoum (ISO); 3-(3-biphenyl-4-yl-1,2,3,4-tetrahydro-1-naphthyl)-4-hydroxycoumarin	259-978-4	56073-07-5	Repr. 1B Acute Tox. 1 Acute Tox. 1 Acute Tox. 1 STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1	H360D H330 H310 H300 H372 (blood) H400 H410	GHS08 GHS06 GHS09 Dgr	H360D H330 H310 H300 H372 (blood) H410		Repr. 1B; H360D: C ≥ 0,003 % STOT RE 1; H372 (blood): C ≥ 0,02 % STOT RE 2; H373 (blood): 0,002 % ≤ C < 0,02 % M = 10 M = 10’
‘607-172-00-1	brodifacoum (ISO); 4-hydroxy-3-(3-(4′-bromo-4-biphenylyl)-1,2,3,4-tetrahydro-1-naphthyl)coumarin	259-980-5	56073-10-0	Repr. 1A Acute Tox. 1 Acute Tox. 1 Acute Tox. 1 STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1	H360D H330 H310 H300 H372 (blood) H400 H410	GHS08 GHS06 GHS09 Dgr	H360D H330 H310 H300 H372 (blood) H410		Repr. 1A; H360D: C ≥ 0,003 % STOT RE 1; H372 (blood): C ≥ 0,02 % STOT RE 2; H373 (blood): 0,002 % ≤ C < 0,02 % M = 10 M = 10’
‘607-375-00-5	flocoumafen (ISO); reaction mass of: cis-4-hydroxy-3-(1,2,3,4-tetrahydro-3-(4-(4-trifluoromethylbenzyloxy)phenyl)-1-naphthyl)coumarin and trans-4-hydroxy-3-(1,2,3,4-tetrahydro-3-(4-(4-trifluoromethylbenzyloxy)phenyl)-1-naphthyl)coumarin	421-960-0	90035-08-8	Repr. 1B Acute Tox. 1 Acute Tox. 1 Acute Tox. 1 STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1	H360D H330 H310 H300 H372 (blood) H400 H410	GHS08 GHS06 GHS09 Dgr	H360D H330 H310 H300 H372 (blood) H410		Repr. 1B; H360D: C ≥ 0,003 % STOT RE 1; H372 (blood): C ≥ 0,05 % STOT RE 2; H373 (blood): 0,005 % ≤ C < 0,05 % M = 10 M = 10’
‘607-623-00-2	diisobutyl phthalate	201-553-2	84-69-5	Repr. 1B	H360Df	GHS08 Dgr	H360Df’
‘613-166-00-X	flumioxazin (ISO); 2-[7-fluoro-3-oxo-4-(prop-2-yn-1-yl)-3,4-dihydro-2H-1,4-benzoxazin-6-yl]-4,5,6,7-tetrahydro-1H-isoindole-1,3(2H)-dione	—	103361-09-7	Repr. 1B Aquatic Acute 1 Aquatic Chronic 1	H360D H400 H410	GHS08 GHS09 Dgr	H360D H410		M = 1 000 M = 1 000 ’
‘613-121-00-4	chlorsulfuron (ISO); 2-chloro-N-[[(4-methoxy-6-methyl-1,3,5-triazin-2- yl)amino]carbonyl]benzenesulphonamide	265-268-5	64902-72-3	Aquatic Acute 1 Aquatic Chronic 1	H400 H410	GHS09 Wng	H410		M = 1 000 M = 100’
‘616-011-00-4	N,N-dimethylacetamide	204-826-4	127-19-5	Repr. 1B Acute Tox. 4* Acute Tox. 4*	H360D*** H332 H312	GHS08 GHS07 Dgr	H360D*** H332 H312’
‘616-037-00-6	acetochlor (ISO); 2-chloro-N-(ethoxymethyl)-N-(2-ethyl-6-methylphenyl)acetamide	251-899-3	34256-82-1	Carc. 2 Repr. 2 Acute Tox. 4 STOT SE 3 STOT RE 2 Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H351 H361f H332 H335 H373 (kidney) H315 H317 H400 H410	GHS08 GHS07 GHS09 Wng	H351 H361f H332 H335 H373 (kidney) H315 H317 H410		M = 1 000 M = 100’
‘616-207-00-X	polyhexamethylene biguanide hydrochloride; PHMB	—	32289-58-0 27083-27-8	Carc. 2 Acute Tox. 2 Acute Tox. 4 STOT RE 1 Eye Dam. 1 Skin Sens. 1B Aquatic Acute 1 Aquatic Chronic 1	H351 H330 H302 H372 (respiratory tract) (inhalation) H318 H317 H400 H410	GHS08 GHS06 GHS05 GHS09 Dgr	H351 H330 H302 H372 (respiratory tract) (inhalation) H318 H317 H410		M = 10 M = 10’

(c)

the following entries are inserted in accordance with the order of the index numbers:

Index No	International Chemical Identification	EC No	CAS No	Classification		Labelling			Specific Conc. Limits, M-factors	Notes
Index No	International Chemical Identification	EC No	CAS No	Hazard Class and Category Code(s)	Hazard statement Code(s)	Pictogram, Signal Word Code(s)	Hazard statement Code(s)	Suppl. Hazard statement Code(s)	Specific Conc. Limits, M-factors	Notes
‘005-020-00-3	disodium octaborate anhydrous; [1] disodium octaborate tetrahydrate [2]	234-541-0 [1] 234-541-0 [2]	12008-41-2 [1] 12280-03-4 [2]	Repr. 1B	H360FD	GHS08 Dgr	H360FD’
‘014-046-00-4	e-glass microfibres of representative composition; [Calcium-aluminium-silicate fibres with random orientation with the following representative composition (% given by weight): SiO2 50,0-56,0 %, Al2O3 13,0-16,0 %, B2O3 5,8-10,0 %, Na2O < 0,6 %, K2O < 0,4 %, CaO 15,0-24,0 %, MgO < 5,5 %, Fe2O3 < 0,5 %, F2 < 1,0 %. Process: typically produced by flame attenuation and rotary process. (Additional individual elements may be present at low levels; the process list does not preclude innovation).]	—	—	Carc. 1B	H350i	GHS08 Dgr	H350i			A’
‘014-047-00-X	glass microfibres of representative composition; [Calcium-aluminium-silicate fibres with random orientation with the following composition (% given by weight): SiO2 55,0-60,0 %, Al2O3 4,0-7,0 %, B2O3 8,0-11,0 %, ZrO2 0,0-4,0 %, Na2O 9,5-13,5 %, K2O 0,0-4,0 %, CaO 1,0-5,0 %, MgO 0,0-2,0 %, Fe2O3 < 0,2 %, ZnO 2,0-5,0 %, BaO 3,0-6,0 %, F2 < 1,0 %. Process: typically produced by flame attenuation and rotary process. (Additional individual elements may be present at low levels; the process list does not preclude innovation).]	—	—	Carc. 2	H351 (inhalation)	GHS08 Wng	H351 (inhalation)			A’
‘029-015-00-0	copper thiocyanate	214-183-1	1111-67-7	Aquatic Acute 1 Aquatic Chronic 1	H400 H410	GHS09 Wng	H410	EUH032	M = 10’
‘029-016-00-6	copper(II) oxide	215-269-1	1317-38-0	Aquatic Acute 1 Aquatic Chronic 1	H400 H410	GHS09 Wng	H410		M = 100’
‘029-017-00-1	dicopper chloride trihydroxide	215-572-9	1332-65-6	Acute Tox. 4 Acute Tox. 3 Aquatic Acute 1 Aquatic Chronic 1	H332 H301 H400 H410	GHS06 GHS09 Dgr	H332 H301 H410		M = 10’
‘029-018-00-7	tetracopper hexahydroxide sulphate; [1] tetracopper hexahydroxide sulphate hydrate [2]	215-582-3 [1] 215-582-3 [2]	1333-22-8 [1] 12527-76-3 [2]	Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1	H302 H400 H410	GHS07 GHS09 Wng	H302 H410		M = 10’
‘029-019-01-X	copper flakes (coated with aliphatic acid)	—	—	Acute Tox. 3 Acute Tox. 4 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1	H331 H302 H319 H400 H410	GHS06 GHS09 Dgr	H331 H302 H319 H410		M = 10’
‘029-020-00-8	copper(II) carbonate--copper(II) hydroxide (1:1)	235-113-6	12069-69-1	Acute Tox. 4 Acute Tox. 4 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1	H332 H302 H319 H400 H410	GHS07 GHS09 Wng	H332 H302 H319 H410		M = 10’
‘029-021-00-3	copper dihydroxide; copper(II) hydroxide	243-815-9	20427-59-2	Acute Tox. 2 Acute Tox. 4 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1	H330 H302 H318 H400 H410	GHS06 GHS05 GHS09 Dgr	H330 H302 H318 H410		M = 10’
‘029-022-00-9	bordeaux mixture; reaction products of copper sulphate with calcium dihydroxide	—	8011-63-0	Acute Tox. 4 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1	H332 H318 H400 H410	GHS07 GHS05 GHS09 Dgr	H332 H318 H410		M = 10’
‘029-023-00-4	copper sulphate pentahydrate	231-847-6	7758-99-8	Acute Tox. 4 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1	H302 H318 H400 H410	GHS07 GHS05 GHS09 Dgr	H302 H318 H410		M = 10’
‘082-013-00-1	lead powder; [particle diameter < 1 mm]	231-100-4	7439-92-1	Repr. 1A Lact.	H360FD H362	GHS08 Dgr	H360FD H362		Repr. 1A; H360D: C ≥ 0,03 %’
‘082-014-00-7	lead massive: [particle diameter ≥ 1 mm]	231-100-4	7439-92-1	Repr. 1A Lact.	H360FD H362	GHS08 Dgr	H360FD H362’
‘605-040-00-8	hydroxyisohexyl 3-cyclohexene carboxaldehyde (INCI); reaction mass of 4-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde and 3-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde; [1] 4-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde; [2] 3-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde [3]	- [1] 250-863-4 [2] 257-187-9 [3]	130066-44-3 [1] 31906-04-4 [2] 51414-25-6 [3]	Skin Sens. 1A	H317	GHS07 Wng	H317’
‘607-716-00-8	bromadiolone (ISO); 3-[3-(4′-bromobiphenyl-4-yl)-3-hydroxy-1-phenylpropyl]-4-hydroxy-2H-chromen-2-one	249-205-9	28772-56-7	Repr. 1B Acute Tox. 1 Acute Tox. 1 Acute Tox. 1 STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1	H360D H330 H310 H300 H372 (blood) H400 H410	GHS08 GHS06 GHS09 Dgr	H360D H330 H310 H300 H372 (blood) H410		Repr. 1B; H360D: C ≥ 0,003 % STOT RE 1; H372 (blood): C ≥ 0,005 % STOT RE 2; H373 (blood): 0,0005 % ≤ C < 0,005 % M = 1 M = 1’
‘607-717-00-3	difethialone (ISO); 3-[3-(4′-bromobiphenyl-4-yl)-1,2,3,4-tetrahydronaphthalen-1-yl]-4-hydroxy-2H-1-benzothiopyran-2-one	—	104653-34-1	Repr. 1B Acute Tox. 1 Acute Tox. 1 Acute Tox. 1 STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1	H360D H330 H310 H300 H372 (blood) H400 H410	GHS08 GHS06 GHS09 Dgr	H360D H330 H310 H300 H372 (blood) H410	EUH070	Repr. 1B; H360D: C ≥ 0,003 % STOT RE 1; H372 (blood): C ≥ 0,02 % STOT RE 2; H373 (blood): 0,002 % ≤ C < 0,02 % M = 100 M = 100’
‘607-718-00-9	perfluorononan-1-oic acid [1] and its sodium [2] and ammonium [3] salts	206-801-3 [1] [2] [3]	375-95-1 [1] 21049-39-8 [2] 4149-60-4 [3]	Carc. 2 Repr. 1B Lact. Acute Tox. 4 Acute Tox. 4 STOT RE 1 Eye Dam. 1	H351 H360Df H362 H332 H302 H372 (liver, thymus, spleen) H318	GSH08 GSH07 GHS05 Dgr	H351 H360Df H362 H332 H302 H372 (liver, thymus, spleen) H318’
‘607-719-00-4	dicyclohexyl phthalate	201-545-9	84-61-7	Repr. 1B Skin Sens. 1	H360D H317	GHS08 GHS07 Dgr	H360D H317’
‘608-067-00-3	3,7-dimethylocta-2,6-dienenitrile	225-918-0	5146-66-7	Muta. 1B	H340	GHS08 Dgr	H340’
‘612-288-00-0	bupirimate (ISO); 5-butyl-2-ethylamino-6-methylpyrimidin-4-yl dimethylsulphamate	255-391-2	41483-43-6	Carc. 2 Skin Sens. 1B Aquatic Chronic 1	H351 H317 H410	GHS08 GHS07 GHS09 Wng	H351 H317 H410		M = 1’
‘612-289-00-6	triflumizole (ISO); (1E)-N-[4-chloro-2-(trifluoromethyl)phenyl]-1-(1H-imidazol-1-yl)-2-propoxyethanimine	—	68694-11-1	Repr. 1B Acute Tox. 4 STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H360D H302 H373 (liver) H317 H400 H410	GHS08 GHS07 GHS09 Dgr	H360D H302 H373 (liver) H317 H410		M = 1 M = 1’
‘616-218-00-X	benzovindiflupyr (ISO); N-[9-(dichloromethylene)-1,2,3,4-tetrahydro-1,4-methanonaphthalen-5-yl]-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide	—	1072957-71-1	Acute Tox. 3 Acute Tox. 3 Aquatic Acute 1 Aquatic Chronic 1	H331 H301 H400 H410	GHS06 GHS09 Dgr	H331 H301 H410		M = 100 M = 100’
‘616-219-00-5	fluopyram (ISO); N-{2-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]ethyl}-2-(trifluoromethyl)benzamide	—	658066-35-4	Aquatic Chronic 2	H411	GHS09	H411’
‘616-220-00-0	pencycuron (ISO); 1-[(4-chlorophenyl)methyl]-1-cyclopentyl-3-phenylurea	266-096-3	66063-05-6	Aquatic Acute 1 Aquatic Chronic 1	H400 H410	GHS09 Wng	H410		M = 1 M = 1’
‘617-023-00-2	tert-butyl hydroperoxide	200-915-7	75-91-2	Muta. 2	H341	GHS08 Wng	H341’